Dendritic Cell Vaccine Shows Promise in High-Risk Multiple Myeloma Patients

A dendritic cell vaccine has demonstrated safety and immunogenicity when administered before and after autologous stem cell transplant (ASCT) in patients with high-risk multiple myeloma, according to a study published in Clinical Cancer Research.

For multiple myeloma, a chronic and incurable cancer, dendritic cell vaccines are seen as a potential avenue to harness the patient's immune system and achieve remission. The study, from researchers at Moffitt Cancer Center, targeted patients with high-risk disease who still had active myeloma after induction therapy and before receiving ASCT, as these patients have the greatest need for the vaccine.

Dendritic cells play a crucial role in the immune system by processing foreign proteins and presenting them to other immune cells to trigger an immune response. In this study, patients' dendritic cells were engineered to express a protein called survivin, which is associated with poor outcomes when highly expressed in multiple myeloma. The goal was to induce an immune response against survivin and potentially extend remission.

The trial involved 13 multiple myeloma patients who received one vaccine dose before ASCT and another approximately 21 days post-transplant. The results were promising: the vaccine was well tolerated, with minor adverse effects, and it induced survivin-specific immune responses in patients.

Approximately 35% of patients showed an increase in circulating survivin-specific CD4 T cells, while about 30% showed increased CD8 T cells. Antibodies against survivin peptides were detected in 9 out of 13 patients after vaccination and ASCT. Overall, 85% of patients had either a T-cell response or an antibody response against survivin.

Seven patients experienced an improved clinical response at 90 days post-transplant, all of whom exhibited survivin-specific immune responses. After a median follow-up of 4.2 years, six of these patients remained alive and disease-free, with an estimated four-year progression-free survival rate of 71%.

The study suggests that targeting survivin with a vaccine-based approach can induce immune responses and improve patient outcomes. Larger, randomized studies are needed to confirm these findings and explore the potential benefits of administering the vaccine earlier in the disease course to prevent aggressive forms of myeloma. However, the researchers noted limitations, including the unique patient population and the rapidly evolving treatment landscape for myeloma.